Naturland Holding ZrtBUD:NATURLAND 61 3-Year ROIIC % is 231.66 as of Dec. 2024, which is 69% above its 10-year median of 137.02. GuruFocus rates BUD:NATURLAND with a GF Score™ of 61/100 and a GF Value™ of Ft2,882.33 (Fairly Valued). The stock has 5 warning signs investors should review. Among 942 Drug Manufacturers companies, Naturland Holding Zrt ranks better than 95.12% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Naturland Holding Zrt's 3-Year ROIIC % for the quarter that ended in Dec. 2024 was 231.66%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Naturland Holding Zrt's 3-Year ROIIC % or its related term are showing as below:
BUD:NATURLAND's 3-Year ROIIC % is ranked better than 95.12% of 942
companies
in the Drug Manufacturers industry
Industry Median: 3.72
vs BUD:NATURLAND: 231.66
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Naturland Holding Zrt 3-Year ROIIC % Related Terms
Naturland Holding Zrt 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Naturland Holding Zrt's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUD:NATURLAND vs ZTS, UTHR, VTRS: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Naturland Holding Zrt's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Naturland Holding Zrt 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Naturland Holding Zrt's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Naturland Holding Zrt's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Naturland Holding Zrt (BUD:NATURLAND) has a 3-Year ROIIC % of 231.66 as of Dec. 2024. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Naturland Holding Zrt and its competitors. This is 69% above median its historical median of 137.02. Over the past decade, Naturland Holding Zrt's 3-Year ROIIC % has ranged from 42.37 to 231.66. According to the industry distribution chart, Naturland Holding Zrt ranks #46 out of 942 companies in the Drug Manufacturers industry, placing it in the top 4.9%.
Is Naturland Holding Zrt's 3-Year ROIIC % too high?
Naturland Holding Zrt's current 3-Year ROIIC % of 231.66 is 69% above median its 10-year median of 137.02. Over the past 10 years, this metric has ranged from a low of 42.37 to a high of 231.66. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. Naturland Holding Zrt's value of 231.66 is 6127.4% above this industry median. Based on the distribution chart, Naturland Holding Zrt ranks #46 out of 942 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Naturland Holding Zrt has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Naturland Holding Zrt's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Naturland Holding Zrt ranks #46 out of 942 companies for 3-Year ROIIC %. This places Naturland Holding Zrt in the top 5% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.72. Naturland Holding Zrt's value of 231.66 is 6127.4% above this benchmark. Historically, Naturland Holding Zrt's own 3-Year ROIIC % has ranged from 42.37 to 231.66 over the past decade. While the company's 10-year median is 137.02 vs. the industry median of 3.72, Naturland Holding Zrt has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Naturland Holding Zrt's current 3-Year ROIIC % of 231.66 is 6127.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Naturland Holding Zrt and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Naturland Holding Zrt's current 3-Year ROIIC % is 231.66, which is 69% above median its own 10-year median of 137.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturland Holding Zrt stock overvalued right now?
Based on GuruFocus' analysis, Naturland Holding Zrt (BUD:NATURLAND) is currently considered Fairly Valued. The stock's GF Value™ is Ft2,882.33, compared to a current price of Ft2,820.00 — trading 2.2% below its estimated fair value. The current 3-Year ROIIC % is 231.66, which is 69% above median its 10-year median of 137.02 and 6127.4% above the Drug Manufacturers industry median of 3.72. Naturland Holding Zrt's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Naturland Holding Zrt (BUD:NATURLAND), the current 3-Year ROIIC % is 231.66 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Naturland Holding Zrt (BUD:NATURLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Naturland Holding Zrt stock appears to be undervalued.
The current stock price of Ft2,820.00 is trading 2.2% below its estimated GF Value™ of Ft2,882.33.
GuruFocus considers Naturland Holding Zrt to be Fairly Valued.
Key valuation signals for BUD:NATURLAND:
3-Year ROIIC %: 231.66 (69% above median its 10-year median of 137.02)
GF Value™: Ft2,882.33 vs. price of Ft2,820.00 (2.2% below fair value)
Industry Position: 6127.4% above the Drug Manufacturers median (#46 of 942)
No single metric tells the full story. See the BUD:NATURLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Naturland Holding Zrt thro9ugh its subsidiaries engage in the production of pharmaceutical products. It engages in the development, production, and wholesale of dietary supplements and cosmetics, herbal medicine, teas, and essential oils. The firm offers tablets, suppositories, ointments, and ophthalmic base solutions.
61GF Score
Get the complete analysis for BUD:NATURLAND
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NATURLAND has been successfully added to your 
